Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
4 March 2026
But now it must show that varseta-M can move into a registrational trial.
2 March 2026
The first fruit of a long-standing deal with Roche enters phase 1 in March.
28 February 2026
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
27 February 2026
The company will license EGFR and cMet inhibitors from Celyn.
27 February 2026
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
26 February 2026
After several discontinuations, a new ADC enters the clinic.
26 February 2026
TARA-002 goes from looking better than Inlexzo to seeming rather worse.